Evidence map›Paper›PMID 42877848›Full record

ReviewThe Journal of clinical and aesthetic dermatology2026

Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients-Part 1.

James Q Del Rosso, Lauren Lam, Diego Ruiz Dasilva, Joshua Burshtein, Christopher G Bunick, Lara Shqair, Andrea Murina, Katrina H Lee, Jennifer Hsiao, Tiffany Mayo and 6 more

Abstract readReview
In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

James Q Del RossoDr. Del Rosso is with JDR Dermatology Research, Las Vegas, Nevada.
Lauren LamDr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation, Calgary, Canada.
Diego Ruiz DasilvaDr. Dasilva is with Eastern Virginia Medical School, Norfolk, Virginia.
Joshua BurshteinDr. Burshtein is with the Department of Dermatology, University of Illinois Chicago, Chicago, Illinois.
Christopher G BunickDr. Bunick is with the Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Lara ShqairMs. Shqair is with the Icahn School of Medicine at Mount Sinai, New York, New York.
Andrea MurinaDr. Murina is with the Tulane University School of Medicine, New Orleans, Louisiana.
Katrina H LeeDrs. Lee and Hsiao are with the Department of Dermatology, Keck School of Medicine of USC, Los Angeles, California.
Jennifer HsiaoDrs. Lee and Hsiao are with the Department of Dermatology, Keck School of Medicine of USC, Los Angeles, California.
Tiffany MayoDr. Mayo is with the University of Alabama at Birmingham, Birmingham, Alabama.
Graham LitchmanDrs. Litchman and Farley are with Vivida Dermatology, Las Vegas, Nevada.
Andrew FerrierDr. Ferrier is with the Division of Dermatology, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada.
Michael PayetteDr. Payette is with Central Connecticut Dermatology, Cromwell, Connecticut.
Steve DaveluyDr. Daveluy is with the Department of Dermatology, Wayne State University, Detroit, Michigan.
Victoria FarleyDrs. Litchman and Farley are with Vivida Dermatology, Las Vegas, Nevada.
Vivian ShiDr. Shi is with the Department of Dermatology, University of Washington, Seattle, Washington.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disorder that usually starts in the second or third decade of life and has a profound negative impact on quality of life of those who are affected. HS presents with both inflammatory and cicatricial lesions that are often markedly symptomatic, including pain and purulent discharge, and commonly affect areas that are intertriginous, resulting in additional frictional and mechanical discomfort. The pathophysiology is complex and incompletely understood and results in changes that are transcutaneous, involving the epidermis, superficial dermis, and deep dermis with inflammation, scarring, and sinus tract (tunnel) formation. Effective treatment warrants a timely, accurate diagnosis with early intervention with systemic therapy needed to prevent progression of disease in cases that do not remain as mild, well managed, and stable. The goal of this 4-part article series on HS is to be practical, reasonably comprehensive, and clinically useful as a "guidance tool" to assist clinicians in managing HS. This first article of the series includes a disease overview of HS, an overview of pathophysiology, important details of physical examination, suggested laboratory evaluations, and the significance and rational assessment of potential comorbidities.

Indexed as

abscessesdraining tunnelsHidradenitis suppurativanodulessinus tracts

Identifiers

PMID42877848
PMCPMC13668087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.